

9. Beneficiaries under the program are exempted from the payment of any contribution.

10. Services and goods obtained from outside Québec are not covered by this program except those provided by a pharmacist with whom the Board has entered into a special agreement for that purpose, if the pharmacy is situated in a region bordering on Québec and no Québec pharmacy within a radius of 32 kilometres of the pharmacy serves the public.

11. The Board is to periodically report to the Minister of Health and Social Services on the costs incurred in connection with this program, on such terms and conditions as may be agreed on. The reports are not to contain personal information.

12. The Board is to post this program on its website not later than the day the program takes effect. Any modifications under section 4 are also to be posted on the website not later than the day they take effect, so as to inform the public.

13. This program takes effect on 17 March 2022 and ends on 31 March 2023.

SCHEDULE A

Persons eligible for the program

Paxlovid^{MC} (nirmatrelvir and ritonavir):

A person with COVID-19 (confirmed by NAAT or antigen test) with mild to moderate symptoms for 5 or fewer days, not hospitalized because of COVID-19, who is at high risk of COVID-19 life-threatening complications, from among the **following list**:

—an adult with moderate to severe immunosuppression caused by an underlying condition or its treatment (irrespective of vaccination status);

—an unvaccinated or partially vaccinated person (incomplete primary vaccination) and:

- 60 years of age or older; or
- 18 years of age or older with at least one of the following conditions:
 - hemoglobinopathy;
 - chronic renal failure;
 - chronic hepatic insufficiency;
 - obesity (increased risk with BMI \geq 35);
 - diabetes (increased risk if uncontrolled);

–confirmed high blood pressure (increased risk if uncontrolled);

- atherosclerotic cardiovascular disease;
- heart failure, NYHA functional class II to IV;
- chronic lung disease (ex. COPD, moderate to severe asthma).

—an adolescent weighing at least 40 kg or a pregnant woman:

–with at least one condition entailing a high risk of COVID-19 life-threatening complications from among the above list;

–and who is not adequately protected/vaccinated or a suboptimal vaccination response is anticipated in the clinician's opinion;

–and after discussion with, for example, a specialist in pediatric infectiology or maternal foetal medicine;

—exceptionally, an adult adequately protected/vaccinated with very high risk of COVID-19 complications (ex. very advanced age, several comorbidities among the above list, especially if uncontrolled, and suboptimal protection against the circulating variant, anticipated despite full primary vaccination, after discussion with a specialist physician or an experienced colleague.

SCHEDULE B

Type of pharmaceutical treatments	Unit format	Unit cost	Maximum quantity of units per service
Paxlovid ^{MC} (nirmatrelvir and ritonavir)	1 package containing 20 tablets of nirmatrelvir and 10 tablets of ritonavir	\$800	1

105600

Gouvernement du Québec

O.C. 320-2022, 16 March 2022

Extension of the effect of the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic

WHEREAS the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic (2021, chapter 26) was assented to on 23 September 2021;

WHEREAS, under the first paragraph of section 5 of the Act, the Act comes into force on 23 September 2021 and ceases to have effect on 23 October 2021;

WHEREAS, under the second paragraph of section 5 of the Act, however, the Government may, before the expiry date, extend the effect of the Act for a period of 30 days and, on the same conditions, make any other extension;

WHEREAS, under the third paragraph of section 5 of the Act, despite the preceding paragraphs, the Act may not have effect beyond the date on which the public health emergency, declared by Order in Council 177-2020 dated 13 March 2020 and renewed in accordance with section 119 of the Public Health Act (chapter S-2.2), ends;

WHEREAS the effect of the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic was extended until 21 November 2021 by Order in Council 1344-2021 dated 20 October 2021, until 21 December 2021 by Order in Council 1454-2021 dated 17 November 2021, until 20 January 2022 by Order in Council 1616-2021 dated 15 December 2021, until 19 February 2022 by Order in council 90-2022 dated 19 January 2022 and until 21 March 2022 by Order in council 178-2022 dated 16 February 2022;

WHEREAS the public health emergency was renewed in accordance with section 119 of the Public Health Act until 25 March 2022 by Order in Council 272-2022 dated 16 March 2022;

WHEREAS it is expedient to extend the effect of the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic for a period of 30 days;

IT IS ORDERED, therefore, on the recommendation of the Minister of Public Security:

THAT the effect of the Act to establish a perimeter around certain places in order to regulate demonstrations in relation to the COVID-19 pandemic (2021, chapter 26) be extended until 20 April 2022, unless the public health emergency declared by Order in Council 177-2020 dated 13 March 2020 and renewed in accordance with section 119 of the Public Health Act (chapter S-2.2) ends before that date.

YVES OUELLET
Clerk of the Conseil exécutif

105597